Consorzio per Valutazioni

BiologiChe e FarmaCologiChewww.cvbf.net info@cvbf.net

ABOUT US

Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) is a not for profit clinical research organi-sation, founded in 2000, with the mission to perform research and education in the pharmaceutical field integrating management, monitoring, regulatory, clinical, epidemiological, economical, methodological and statistical expertise.

All activities are carried out in partnership with its partners: University of Bari “Aldo Moro” (UniBA), Gianni Benzi Pharmacological Research Foundation (FGB), Italian Group for Pharmacoeconomic Studies (GISF) PHArmaceutical Research Management srl (PHARM) and Mediterranea Associazione per lo Sviluppo Lo-cale (MED).

On May 2015, the CVBF branch office in Tirana has been opened, acting as a Contract Research Or-ganisation (CRO) to conduct GCP (Good Clinical Practice) clinical trials and supporting pharmaceutical companies willing to conduct clinical research in Albania.

CVBF is coordinator of TEDDY - European Network of Excellence for Paediatric Clinical Research, an inde-pendent multidisciplinary, multinational Network (member of EnprEMA) aimed at facilitating the perfor-mance of good quality paediatric studies and research.

• Registered in the Register of Legal Entities, Prefecture of Pavia, No. 205/2004

• Registered in the National Register of Research of the Ministry of Education, University and Research (MIUR) (code: 56527NPW) on November 11th, 2004

• Granted Quality Certification since 2004, last renewal issued by Bureau Veritas (certificate ISO 9001:2008 n. IT252163) on December 16th, 2013

• Certified by the Italian Medicines Agency (AIFA) as a CRO (Contract Research Organization) in the field of the clinical research in accordance with art. 7 and 8 of Ministerial Decree 31/3/2008 since 2009

• Accredited by the Ministry of Health – National Commission for Continuing Education (Age.Na.S.) as a Continuing Medical Education (CME) provider and registered in the list of the authorised Distance Education (FAD) providers since June 2011

• Registered in EudraVigilance as non-commercial Sponsor of clinical trials (ORG13237) since November 23th, 2012

• Accredited by the Italian Medicines Agency (AIFA) and the European Medicines Agency (EMA) as a non-profit promoter of clinical trials

• Member of the Italian Association of CROs (AICRO) and of several networks promoting clinical trials

CERTIFICATES AND ACCREDITATIONS

The institutional aims of CVBF are:

• to promote the integration of the European pharmaceutical systems by developing knowledge and research methodologies adequate to support the complex procedures to be followed for the devel-opment of drugs

• to transfer the know-how for the conduct of CTs consistent with the European standards to third Coun-tries and promote the efficient and effective use of public funds in clinical research

• to encourage the development of innovative products for the treatment of rare and/or paediatric diseases

• to coordinates and participate in National and European research projects

• to promote educational activities, in particular providing educational contribution in the field of the continuing education programmes (CME)

• to support the rational use of medicinal products according to the current legislation

• to promote knowledge and access to the results of biomedical research and accelerate their use by patients.

MISSION

The main fields of interest are life sciences and biotechnologies, drug development for small populations (paediatric and rare diseases), research management, clinical trial methodology, monitoring and statis-tics, ethics and pharmacovigilance.

AREAS OF INTEREST AND ACTIVITIES

CLINICAL TRIALS REGULATORY RESEARCH TRAINING

Clinical trialsCVBF has developed significant expertise in the field of clinical trials acting as sponsor and CRO (Contract Research Organization), authorised by the Italian Medicines Agency (AIFA) since 2009, by providing specific services related to clinical trial management.

In the context of the EU-funded projects (DEEP; CloSed; GAPP; NEOVANC), CVBF is particularly involved in the management of ethical procedures for multi-national paediatric trials in order to guarantee adequate ethical standard in EU and non-EU countries. In particular, CVBF participated in the international discussion and public consultation on the revision of Directive 2001/20/EC and on the proposal for the new EU Regulation on Clinical Trials.

Regulatory activitiesThe regulatory activity includes the development and supervision of dossiers and documen-tation regarding national and European authorisation procedures for medicinal products (Orphan Designation, Development Plan for Children, Scientific Advice, Centralised Market-ing Authorisation, Advanced Therapy, etc.), including authorisation to perform national and

multinational clinical trial activities with access to EudraVigilance and EUDRACT. With reference to clinical trials, CVBF acts as a Contract Research Organisation (CRO) for several activities: regulatory submissions, clinical sites selection and contracting, data management, monitoring, statistics, pharmacovigilance, medical reporting.

AREAS OF INTEREST AND ACTIVITIES

AREAS OF INTEREST AND ACTIVITIES

Scientific researchResearch activities in the pharmacological field are mainly conducted in the context of na-tional and EU funded projects. In particular, they are focused on the development and ap-plication of innovative methodologies in clinical trials for small populations (e.g. rare diseases, paediatrics), the management of interventional, non-interventional, health technology as-sessment and pharmacoeconomic studies, and disease registries.

Among the several publications the Consortium has authored many scientific peer-reviewed papers, a paediatric monograph and 2 single-issue publications on specialised journals.

TrainingAddressed to public bodies, research institutes and private companies, CVBF’s training activ-ities support the Consortium’s areas of expertise. CVBF is also involved in the design and exe-cution of Continuing Medical Education (CME) programmes and is accredited by the Italian

Committee for Continuing Medical Education (Age.Na.S.) as a CME Provider to carry out residential and e-learning courses. In May 2015 CVBF organised also the first ECM Open Meeting in Tirana in collaboration with the University Hospital Center “Mother Teresa” (UHCT).

CVBF has developed significant expertise as Coordinator of several national and international projects and participates as Partner in many research projects funded by the European Commission.

RESEARCH PROJECTS

TEDDY - European Network of Excellence for Paediatric Clinical ResearchTEDDY was created as a Network of Excellence and funded under the Sixth EU Framework Programme for Research and Technological Development (FP6) with the goal to support and strengthen scientific and technological excellence in the paediatric sector in Europe.

Since 2010 it has revised its organisation and gathered research centres and groups willing to be engaged in paediatric clinical research development. Today TEDDY is an independent multidisciplinary and multi-national Network composed of partners from 18 countries, where researchers, scientists and health experts are still working together to identify the most appropriate common rules that reflect the specificity of this patient population. The Network aims at facilitating the performance of good quality paediatric studies and research, promoting the availability of safe and effective medicines for children in Europe, by en-couraging the integration of the paediatric pharmacological research activities, the implementation of adequate health policies and the promotion of social awareness on the importance of the paediatric medicines across Europe.

TEDDY is a member of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA).

Network Coordinator: Consorzio per Valutazioni Biologiche e FarmacologicheFunded by: Own resourcesDuration: 2005 - still active

RESEARCH PROJECTS

www.teddynetwork.net

RESEARCH PROJECTS

PedCRIN - Paediatric Clinical Research Infrastructure Network Children’s health is a major societal challenge for Europe and the world, requiring development of pae-diatric medicines and treatments strategies based on evidence derived from clinical trials demonstrating efficacy and safety in infants and children, rather than on uncritical extrapolation from adult data (over 50% of the medicines used for children had not been tested in this specific age group). Conducting clini-cal trials in children requires specific competences and infrastructure. ECRIN-ERIC is a European infrastruc-ture for multinational trial management in any disease area, which does not specifically address the pae-diatric needs in terms of trial management capacity. In its 2016 Roadmap, ESFRI suggested an upgrade of ECRIN to develop a common infrastructure for paediatric trial management through cooperation with the proposes European Paediatric Clinical Trial Research Infrastructure (EPCT-RI).

The resulting PedCRIN project represents a unique opportunity to upgrade the existing ESFRI-landmark ECRIN-ERIC and to improve its business model and financial sustainability, attracting more trials and more Member and Observer countries, involving both scientific communities and government representatives in these strategic discussions.

CVBF is responsible for the development of tools and databases specific for paediatric and neonatal clinical trials.

Project Coordinator: European Clinical Research Infrastructure Network (ECRIN-ERIC) Grant Agreement: 731046 - H2020-INFRADEV-2016-1Funded by: European Commission Duration: 2017 - 2019

STARTING IN 2017

RESEARCH PROJECTS

SMART (Small Medicines Advanced Research Training)SMART is a project aimed at raising the Instytut Pomnik Centrum Zdrowia Dziecka (IPCZD – Poland) staff’s research profile and increase capacity in providing innovative paediatric research methods. A specific training programme is foreseen including the organisation of staff exchanges, face to face courses and summer schools. These activities are oriented to share experience, promote cross-interaction among dis-ciplines and institutions, boost the project’s cohesion and ensure the effective participation of all partners.

SMART is a replicable and exportable interaction model, in which research, innovative enterprise and public administration work together to shape a smart development, sustainable and inclusive strategy to be applied to the development of pediatric medicines.

CVBF acts as internationally-leading research institution providing specific expertise in paediatric medi-cine, clinical trial government and developing, M&S and Extrapolation applications. The University of Bari ‘Aldo Moro’ will provide expertise in new formulation generation.

Project Coordinator: Instytut Pomnik Centrum Zdrowia Dziecka

Grant Agreement: 692327 - H2020-TWINN-2015

Funded by: European Commission

Duration: 2016 - 2018

RESEARCH PROJECTS

CloSed (Clonidine for Sedation of Paediatric Patients in the Intensive Care Unit)CloSed is a 5-year project aimed to perform a multi-centre and multinational paediatric clinical trial stud-ying clonidine, a drug already used for sedation in Paediatric Intensive Care Units (PICUs) but not author-ised in paediatric population.

The ultimate goal is to make a parenteral age-appropriate formulation of clonidine available on the mar-ket for sedation in PICUs and to apply for a Paediatric Use Marketing Authorisation (PUMA). Furthermore, the CloSed project partners will use the findings of the clinical trial to develop and disseminate European consensus guidelines for sedation in critically ill newborns and children, which will support all clinicians across Europe in their decisions.

CVBF is involved in the Project as Third Party of its Partner Gianni Benzi Pharmacological Research Foun-dation, and is responsible for the pharmacovigilance activities.

Project Coordinator: University Hospital Erlangen

Grant Agreement: 602453-FP7-HEALTH-2013-INNOVATION-1

Funded by: European Commission

Duration: 2013 - 2018

www.closed-fp7.eu

RESEARCH PROJECTS

GAPP (GAbapentin in Paediatric pain)The GAPP project intends to improve the therapeutic perspectives of children who suffer from chronic pain, providing them with a drug, gabapentin, which seems to be effective and safe, as already demon-strated in adults, and which was included in the European priority list of off-patent paediatric medicines worthy of research grants. Through the development of a PIP (Paediatric Investigation Plan), appropriate dosages, efficacy and safety of gabapentin in children older than 3 years will be assessed. The project in-volves Italian private companies interested in the development of a new formulation tailored for children, European leading scientific institutions located in France, the Netherlands and UK, and recruiting centres also in Albania, Estonia, France, Germany, Greece, Italy and the Netherlands.

At the end of the project and on the basis of the study results, an application for a Paediatric Use Marketing Authorisation (PUMA) for the treatment of chronic pain in children both as mono-therapy and as adjutant therapy will be submitted.

Project Coordinator: Consorzio per Valutazioni Biologiche e Farmacologiche

Grant Agreement: 602962 - FP7-HEALTH-2013-INNOVATION-1

Funded by: European Commission

Duration: 2013 - 2017

www.pediatricpain.eu

RESEARCH PROJECTS

DEEP (Deferiprone Evaluation in Paediatrics)The DEEP Project is aimed to study the efficacy and safety of deferiprone (the first oral iron chelators developed in Europe) in children affected by β-thalaessemia major and other transfusion dependent haemoglobinopathies. The research activities involve 16 European and non-European partners (including hospital centres, universities, companies and research associations) and comprise 28 recruiting centres in EU (Cyprus, Greece, Italy, United Kingdom) and non-EU (Albania, Egypt, Lebanon, Morocco, Tunisia, Turkey). The project goal is to produce a new oral liquid formulation of deferiprone suitable for paediatric use and to integrate the existing information on deferiprone use in iron overloaded paediatric patients. Throughout the project special attention is paid to the development of information tools, adapted to the different paediatric ages and designed specifically for the children involved in the studies.At the end of the project and on the basis of the study results, an application for a Paediatric Use Market-ing Authorisation (PUMA) for the treatment of iron overloaded paediatric patients affected by transfusion dependent haemoglobinopathies will be submitted.Project Coordinator: Consorzio per Valutazioni Biologiche e FarmacologicheGrant Agreement: 261483 - FP7-HEALTH-F4-2010Funded by: European CommissionDuration: 2011 - 2016

www.deepproject.eu

RESEARCH PROJECTS

GRiP (Global Research in Paediatrics)GRiP is a Network of Excellence with the aim of implementing an infrastructure to stimulate and facilitate the development and the safe use of medicines in children. This goal is especially achieved through a training program addressed to all interested professionals (pharmacologists, clinicians, researchers, etc.) and through an integrated use of the existing research capacities, thus reducing the fragmentation and duplication of activities.

To this purpose, GRiP has developed an International Master in Paediatric Clinical Pharmacology, which will be proposed at global level (Europe, USA, Canada, Japan, China, etc.) and will include the methodo-logical basis for conducting clinical studies and trials in paediatrics.

CVBF is leader of the work-package devoted to paediatric clinical studies and responsible for the devel-opment of innovative methodologies to facilitate the implementation of paediatric clinical trials and for developing contents of one of the ten modules of the International Master of Science in Paediatric Medi-cines Development and Evaluation.

Project Coordinator: Azienda Ospedaliera di Padova

Grant Agreement: 261060 - FP7-HEALTH-F5-2010

Funded by: European Commission

Duration: 2011 - 2017

www.grip-network.org

RESEARCH PROJECTS

NeoVanc (Treatment of late onset bacterial sepsis caused by vancomycin susceptible bacteria in neo-nates and infants aged under three months)NeoVanc is aimed at marketing a new formulation of vancomycin for the treatment of neonatal sepsis in patients up to 3 months of age.

Throughout the project clinical and preclinical studies will be conducted in accordance with the Paedi-atric Investigation Plan (PIP) approved by the Paediatric Committee at the European Medicines Agency. Such studies are aimed at defining the pharmacokinetics of this antibiotic as well as at identifying the optimal dosages for its use in the paediatric population.

The achieved results will support the application for a Paediatric Use Marketing Authorisation (PUMA) of the formulation intended for neonates and infants under 3 months of life.

CVBF is responsible for regulatory management including support to PIP implementation, clinical trial au-thorisation process, data management, setup and management of pharmacovigilance activities.

Project Coordinator: Fondazione Penta

Grant Agreement: 242146 - FP7-HEALTH-2013-INNOVATION-1

Funded by: European Commission

Duration: 2014 - 2019

www.neovanc.org

RESEARCH PROJECTS

NeoMero (European multi-centre network to evaluate pharmacokinetics, safety and efficacy of Meropen-em in neonatal sepsis and meningitis)The NeoMero project aimed at adapting an off-patent medicine to the specific need of paediatric pop-ulations and registering and marketing meropenem, an antibiotic so far used off-label for the treatment of sepsis and bacterial meningitis in neonates. To this end, a paediatric development plan has been set which included the conduction of two clinical studies aimed to evaluate the pharmacokinetics, safety and efficacy profile of this medicine in children under 3 months of age.

The achieved results have supported the application for a Paediatric Use Marketing Authorisation (PUMA) of this product, which will be thus available to the entire paediatric population.

CVBF was responsible of the regulatory aspects, providing scientific and technical support for the develop-ment of the Paediatric Investigation Plan (PIP). In addition CVBF had its own Qualified Person for Pharma-coVigilance (QPPV) registered with EudraVigilance, it was equipped with systems and written SOPs.

Project Coordinator: Fondazione Penta

Grant Agreement: 242146 - FP7-HEALTH-2009-4.2-1

Funded by: European Commission

Duration: 2010 - 2015

www.neomero.org

RESEARCH PROJECTS

ARPEC (Antibiotic resistance and prescribing in European Children)ARPEC was a partnership of several European universities and Health Institutions aiming to develop and implement a novel method of surveillance of antimicrobial consumption and resistance in children in hos-pitals and in primary care across Europe.

The overall aim of the project was to improve antimicrobial prescribing in hospitals and in the community by obtaining up-to-date, clinically relevant data on variation in clinical management and antimicrobial consumption and resistance rates and then to feed this back via a number of educational initiatives to paediatricians in-training and in clinical practice across Europe.

Project Coordinator: St George’s University of London

Grant Agreement: 2009-11-01 - Health Programme

Funded by: European Commission

Duration: 2010 - 2013

www.arpec.sgul.ac.uk

RESEARCH PROJECTS

RESPECT (Relating Expectations and Needs to the Participation and Empowerment of Children in Clinical Trials) RESPECT was aimed to identify the needs and motivations of children and their families with respect to paediatric clinical research and methods to strengthen and motivate the participation of children in pae-diatric clinical trials.

The Project explored the issues raised by children’s participation in medical research by speaking with paediatric patients and their parents, patient support organisations, paediatricians, Ethical Committees and representatives of the pharmaceutical industry to gather their experience, insights and suggestions.

The project enabled to make recommendations for how to empower children such that medical re-searchers respect their interests and can motivate their participation in future clinical trials.

Project Coordinator: Göteborg Paediatric Growth Research Centre

Grant Agreement: 201938 - FP7- HEALTH-2007-4.1-4

Funded by: European Commission

Duration: 2008 - 2011

www.patientneeds.eu

RESEARCH PROJECTS

EU-OrphanThe EuOrphan project developed a free web portal for the collection, cataloguing and dissemination of updated information on medicines for rare diseases designated and/or approved in Europe (EMA) and in the United States (FDA). The specific objectives of the research project were to provide an infrastruc-ture that would allow the concrete evaluation of the therapeutic needs in the field of rare diseases in the U.S.A. and in Europe as well as of existing safety and efficacy data on these drugs.

At the end of the public funding period, CVBF decided to continue the project activities and involved its Partner Gianni Benzi Pharmacological Research Foundation, that, in 2008, took upon itself the responsi-bility to carry on the project and currently provides for the management and updating of the database of drugs for rare diseases. Thanks to a user-friendly interface all information is accessible to healthcare professionals, researchers, companies as well as to patients and their associations.

Project Coordinator: Gianni Benzi Pharmacological Research Foundation

Funded by: Own resources

Duration: 2005 - Ongoing

www.euorphan.com

RESEARCH PROJECTS

InNerMeD-I (Inherited NeuroMetabolic Diseases Information) NetworkInNerMeD-I-Network main result has been the creation of a multi-medial network of information targeted on diagnosis and treatment of iNMDs and based on the collection and exchange of validated information among scientific communities, health professionals, patients, patient associations and all interested stake-holders. iNMDs are a group of rare genetic metabolic diseases that impact on the brain causing mental retardation and progressive neurodegeneration which, if not promptly treated, could end in early death.The project aimed to increase current knowledge on iNMDs and speed up the timely and precise identi-fication of patients who may benefit of the available treatments (experimental and marketed). The Net-work has also favoured biomedical research, straightening research capacities and fostering innovative therapeutic tools derived from the recent scientific advancements. CVBF has been involved in the Project through its Partner Gianni Benzi Pharmacological Research Foundation that was responsible for the project management, dissemination activities, production of ethical and methodological recommendations to be applied in clinical trials and the development of an IT platform. Project Coordinator: Brains for Brain FoundationGrant Agreement: 2012 12 12, Second Health Programme 2008 - 2013Funded by: European CommissionDuration: 2013 - 2015

www.innermed.eu

PARTNERSHIPS

Over the years CVBF has established partnerships at national and international level with hospital centres, universities, companies, research and patient associations as well as public institutes and Ministries:

AL - University Hospital Centre “Mother Teresa” of Tirana AL - Lushnjë HospitalAL - Università Cattolica “Nostra Signora del Buon Consiglio”AL - Universiteti i TiranësBE - European Patients’ Forum BE - Good Clinical Practice Alliance-Europe BE - Universite de Liege - Department of PediatricsBE - Universiteit AntwerpenCA - Apo-Pharma Inc Corp CA - Apotex Inc Corp. CA - The Hospital for Sick ChildrenCH - Brighton Collaboration Foundation

CH - The European Society For Paediatric Infectious Deseases CH - World Health Organization CY - Ministry of Health of the Republic of Cyprus CY - Thalassaemia International FederationCZ - Institute of Physiology of the ASCR CZ - Charles University Prague DE - Charité - Universitätsmedizin BerlinDE - European Society for Paediatric Infectious Diseases DE - Universitatsklinikum FreiburgDE - University Hospital of Hamburg-Eppendorf. Department of Medical PsychologyDE - University Hospital ErlangenDK - Region Hovedstaden, Clinical Genetics Depart-ment, RigshospitaletEE - Sihtasutus Tartu Uelikooli Kliinikum EE - University of Tartu

EG - Cairo University Faculty of MedicineEG - Zagazig University Hospitals EG - Alexandria University Hospital, Faculty of MedicineEG - The Egyptian Thalassemia AssociationES - Fundación para la Cooperación y Salud Interna-cional Carlos IIIES - Fundacion Vasca De Innovacion E Investigacion Sanitarias ES - Hospital Sant Joan de Déu ES - Hospital Universitario Clinico San Carlos ES - Hospital Universitario La PazES - Servicio Madrileño de Salud ES - Synapse Research Management Partners S.LES - Universidad de Barcelona FI - Helsingin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä FR - Assistance Publique - Hopitaux de Paris

FR - Espace Ethique Méditerranéen AP-HM Marseille, Université de la Méditerranée FR - Institut National de la Santé et de la Recherche Médicale FR – Universite Paris Diderot GB - Barts Health NHS Trust GB - European Medicines Agency GB - Medical Research Council - Clinical Trials Unit GB - Saint George’s Hospital Medical School GB - University College London GB - University Of Liverpool GB - Therakind Ltd GB - University of Edinburgh GR - Aristotelio Panepistimio Thessalonikis - Aristotle University of Thessaloniki GR - Geniko Nosokomeio Paidon Αthinon I Agia Sophia AteneGR - National and Kapodistrian University of Athens

HK - University of Hong Kong HR - Sveučilište u Zagrebu, Medicinski fakultetIL - Technion - Israel Institute of Technology IT - Abiogen Pharma SpAIT - Agenzia Italiana del FarmacoIT - Agenzia per i Servizi Sanitari RegionaliIT - AssobiotecIT - Azienda Ospedaliera Antonio Cardarelli IT - Azienda Ospedaliera di PadovaIT - Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello IT - Azienda Ospedaliero Universitaria Consorziale Policlinico di BariIT - Azienda Ospedaliero-Universitaria Modena IT - Chiesi Farmaceutici SpAIT - Community of Mediaterranean Universities IT - Consiglio Superiore SanitàIT - Consorzio Italiano per la Ricerca in Medicina IT - Consiglio Nazionale delle Ricerche IT - Dompé Farmaceutici SpAIT - FarmindustriaIT - Federfarma

IT - Fondazione Brains for Brain IT - Fondazione Italiana Leonardo Giambrone per la Guarigione della Thalassemia IT - Fondazione PENTA -For the treatment and care of children with HIV-Onlus IT - Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus IT - Gruppo Italiano per gli Studi di FarmacoeconomiaIT - High Technology District “Health and Biotech-nology” IT - I.RI.D.I.A. S.r.L. IT - Istituto Giannina Gaslini IT - Istituto Superiore Di Sanita’ IT - Novartis Farma SpAIT - Ospedale Pediatrico Bambino Gesù IT - Pharmaceutical Research Management Srl IT - Roche SpAIT - Sigma-Tau Ind. Farm. Riunite SpAIT - Società Italiana Attività Regolatorie IT - Società Italiana di Farmacologia IT - Società Italiana di Pediatria IT - Società Servizi Telematici Srl

IT - Softeco Sismat S.p.A. IT - Tecnofarmaci S.C.p.A.IT - Università degli Studi “Gabriele D’Annunzio” IT - Università degli Studi di BariIT - Università degli Studi di Milano IT - Università degli Studi di Napoli Federico II IT - Università degli Studi di PaviaJP - National Center for Child Health and Deve-lopment LB - Nini HospitalLT - Viesoji Istaiga Vilniaus Universitto Vaiku Ligonine LT - Vilnius University Children Hospital MA - Hopital 20 Aout de CasablancaMA - Abderrahim Harouchi Children Hospital CHU Ibn RochdPL - Instytut Pomnik Centrum Zdrowia Dziecka PT - Associacao de Saude Infantil de Coimbra RO - Romanian Angel Appeal Foundation SE - Karolinska InstituteSE - Linköpings UniversitetSE - Universitet Göteborg, Paediatric Clinical Trails Group

SI - Univerzitetni Klinicni Center Ljubliana SI - University Children’s Hospital, Ljubljana and the Foundation of Child Neurology NL - Academisch Medisch Centrum bij de Universiteit van Amsterdam NL - Childhood Cancer International NL - Erasmus MC Sophia Children’s Hospital NL - Erasmus Universitair Medisch Centrum Rotterdam NL - Radboud University Nijmegen Medical Centre NL - Vereniging Samenwerkende Ouder – en Patiënt-enorganisatiesNL - Universiteit Leiden TN - Centre National de Greffe de Moelle Osseuse TR - University of Ondokuz Mayis SamsunTR - Hacettepe University Faculty of MedicineTR - Mersin University Faculty of Medicine, Child Health and Diseases HospitalTR - Istanbul University, Cerrahpaşa Faculty of MedicineUS - United States Department of Health and Human Services

PARTNERSHIPS

Consorzio per Valutazioni

BiologiChe e FarmaCologiCheVia Luigi Porta, 14 - 27100 Pavia (Italy) Tel.: +39 0382 25075Via Nicolò Putignani, 178 - 70122 Bari (Italy) Tel.: +39 080 86 41 260Ospedale Pediatrico Giovanni XXIII - Via Amendola 207 - 70124 Bari (Italy)Rruga Prokop Myzeqari, 9 - 1000 Tirana (Albania) Tel.: +355 4 224 6082

www.cvbf.net info@cvbf.net